Restor3d, a leader in personalized musculoskeletal implants, has raised $38 million in a Series A funding round to drive the next stage of growth and innovation in 3D-printed medical devices.
This funding round was led by private investors with participation from existing stakeholders, reflecting strong confidence in Restor3d’s mission to redefine the standard of care in orthopaedic and spine surgery. The capital will be used to expand the company’s commercial footprint, scale manufacturing capabilities, and accelerate product development across its portfolio of patient-specific implants.
Restor3d’s cutting-edge platform combines proprietary biomaterials, advanced 3D printing, and AI-driven design to create highly personalized implants tailored to each patient’s unique anatomy. The technology is currently being used in complex orthopedic procedures, including spine, foot and ankle, and trauma surgeries.
“Our mission has always been to improve surgical outcomes through personalized technology,” said Kurt Jacobus, CEO of Restor3d. “This funding empowers us to scale our vision and bring next-generation implants to more patients, more quickly.”
The investment comes as the medical device industry increasingly embraces personalization and digital integration. With its vertically integrated approach — from digital design to final 3D-printed implant — Restor3d is well-positioned to lead in this evolving landscape.
As part of its growth strategy, the company is also enhancing surgeon training programs and expanding its team to meet growing clinical demand.
